Evidence map›Paper›PMID 39935556›Full record

ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2025

A 12-Step Desensitization Protocol for Calaspargase Pegol-mknl.

Minh H N Nguyen, Amanda Memken, Panida Sriaroon, Monica Hajirawala, Jennifer L R Mayer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Minh H N NguyenDivision of Allergy and Immunology (MN, PS, MH), Department of Pediatrics, University of South Florida Morsani College of Medicine, Tampa, FL.
Amanda MemkenDepartment of Pharmacy (AM), Pediatric Hematology/Oncology, Johns Hopkins All Children's Hospital, St. Petersburg, FL.
Panida SriaroonDivision of Allergy and Immunology (MN, PS, MH), Department of Pediatrics, University of South Florida Morsani College of Medicine, Tampa, FL.
Monica HajirawalaDivision of Allergy and Immunology (MN, PS, MH), Department of Pediatrics, University of South Florida Morsani College of Medicine, Tampa, FL.
Jennifer L R MayerCancer and Blood Disorders Institute (JM), Johns Hopkins All Children's Hospital, St. Petersburg, FL.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asparaginase is a standard treatment for acute lymphoblastic leukemia (ALL) of childhood. As a bacteria-derived enzyme, asparaginase is highly immunogenic, and hypersensitivity reactions (HSRs) routinely lead to drug discontinuation. HSRs remain common even with the introduction of pegaspargase, a PEGylated version of

Indexed as

asparaginasecalaspargasedesensitization protocolhypersensitivityleukemia

Identifiers

PMID39935556
PMCPMC11809534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.